title: Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the CoLaus study.
abstract: BACKGROUND
  This study is aimed to assess the prevalence of awareness, treatment and control of high blood pressure (HBP) and associated factors in a Swiss city.
  
  
  METHODS
  Population-based cross-sectional study of 6182 participants (52.5% women) aged 35-75 years living in Lausanne, Switzerland.
  
  
  METHODS
  HBP was defined as blood pressure >/=140/90 mmHg or current antihypertensive medication.
  
  
  RESULTS
  The overall prevalence of HBP was 36% (95% confidence interval: 35-38%). Among participants with HBP, 63% were aware of it. Among participants aware of HBP, 78% were treated, and among those treated, 48% were controlled (BP <140/90 mmHg). In multivariate analysis, HBP prevalence was associated with older age, male sex, low educational level, high alcohol intake, awareness of diabetes or dyslipidaemia, obesity and parental history of myocardial infarction. HBP awareness was associated with older age, female sex, awareness of diabetes or dyslipidaemia, obesity and parental history of myocardial infarction. HBP control was associated with younger age, higher educational level and no alcohol intake. Alone or in combination, sartans were the most often prescribed antihypertensive medication category (41%), followed by diuretics, beta-blockers, angiotensin converting enzyme inhibitors and calcium channel blockers. Only 31% of participants treated for HBP were taking >/=2 antihypertensive medications.
  
  
  CONCLUSIONS
  Although more than half of all participants with HBP were aware and more than three-quarters of them received a pharmacological treatment, less than half of those treated were adequately controlled.
authors.affiliation: Institute of Social and Preventive Medicine (IUMSP), Vascular Medicine eDepartment of Medicine, University Hospital (CHUV), Lausanne, Switzerland.
authors.forename: Nadia
authors.initials: N
authors.lastname: Danon-Hersch
authors.forename: Pedro
authors.initials: P
authors.lastname: Marques-Vidal
authors.forename: Pascal
authors.initials: P
authors.lastname: Bovet
authors.forename: Arnaud
authors.initials: A
authors.lastname: Chiolero
authors.forename: Fred
authors.initials: F
authors.lastname: Paccaud
authors.forename: Alain
authors.initials: A
authors.lastname: Pécoud
authors.forename: Daniel
authors.initials: D
authors.lastname: Hayoz
authors.forename: Vincent
authors.initials: V
authors.lastname: Mooser
authors.forename: Gérard
authors.initials: G
authors.lastname: Waeber
authors.forename: Peter
authors.initials: P
authors.lastname: Vollenweider
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000428:Alcohol Drinking / Q000453:epidemiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D003920:Diabetes Mellitus / Q000453:epidemiology; D004232:Diuretics / Q000627:therapeutic use; D004363:Drug Utilization; D050171:Dyslipidemias / Q000453:epidemiology; D004522:Educational Status; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000453:epidemiology; D009765:Obesity / Q000453:epidemiology; D015995:Prevalence; D012494:Sampling Studies; D012737:Sex Factors; D013557:Switzerland / Q000453:epidemiology; D014505:Urban Population
chemical_list: D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D004232:Diuretics